Study to Evaluate LB-LR1109
Phase 1
76
about 3.8 years
18+
1 site in VA
What this study is about
Researchers are testing a new drug called LB-LR1109. The trial will be given alone or with atezolizumab in people with advanced cancers like lung cancer, head and neck cancer, kidney cancer, bladder cancer, or melanoma. The goal is to see how safe the drug is and if it works at different doses.
Simplified from trial records by PatientMatch.
What you may be asked to do
- 1.Take Phase 1a: LB-LR1109
- 2.Take Phase 1b: LB-LR1109 and Atezolizumab
Participation Burden
What's physically and logistically required of participants.
Requires travel to a study site
How treatment is administered
Everyone gets the investigational treatment.
Extracted study details
Pulled from the trial record to show what is being tested and what the study is measuring.
atezolizumab
injection (Injection)
Primary: Phase 1a: Incidence of Treatment-Emergent Adverse Events of LB-LR1109 as monotherapy / Phase 1b: Incidence of Treatment-Emergent Adverse Events of LB-LR1109 as combination therapy with atezolizumab, Phase 1a: MTD and/or RP2D of LB-LR1109 as monotherapy in participants with advanced or metastatic solid tumors / Phase 1b: MTD and/or RP2D of LB-LR1109 as combination therapy with atezolizumab in participants with advanced or metastatic NSCLC
Secondary: Phase 1a / 1b: Characterize PK of LB-LR1109 as monotherapy and as combination therapy with atezolizumab, Phase 1a / 1b: Pharmacokinetic profile of LB-LR1109 as monotherapy and as combination therapy with atezolizumab
Oncology